Bristol-Myers Squibb Co (XSWX:BMY) Selling, General, & Admin. Expense: CHF5,828 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
78 GF Score
Price CHF50.31
GF Value CHF45.07
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Selling, General, & Admin. Expense?

Bristol-Myers Squibb Co XSWX:BMY +1.42% 78 Selling, General, & Admin. Expense is CHF5,828 Mil as of Mar. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 78/100 and a GF Value™ of CHF45.07. The stock has 7 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Bristol-Myers Squibb Co's selling, general, & admin. expense for the three months ended in Mar. 2026 was CHF1,273 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF5,828 Mil.


Bristol-Myers Squibb Co  (XSWX:BMY) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Bristol-Myers Squibb Co Selling, General, & Admin. Expense Related Terms


Bristol-Myers Squibb Co Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Selling, General, & Admin. Expense Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,082.49 7,279.52 6,721.23 7,501.92 5,791.07

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,399.62 1,393.01 1,424.22 1,738.04 1,273.06

XSWX:BMY vs PFE, GILD, AMGN: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Selling, General, & Admin. Expense falls into.


XSWX:BMY
78GF Score
Bristol-Myers Squibb Co XSWX:BMY
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF5,828 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of CHF5,828 Mil mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Selling, General, & Admin. Expense of CHF5,828 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Selling, General, & Admin. Expense too high?
Bristol-Myers Squibb Co's current Selling, General, & Admin. Expense is CHF5,828 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Selling, General, & Admin. Expense compare to PFE and GILD?
Bristol-Myers Squibb Co's Selling, General, & Admin. Expense of CHF5,828 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Selling, General, & Admin. Expense is CHF5,828 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Selling, General, & Admin. Expense of CHF5,828 Mil. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current Selling, General, & Admin. Expense is CHF5,828 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Selling, General, & Admin. Expense is CHF5,828 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.

Key valuation signals for XSWX:BMY:

  • Selling, General, & Admin. Expense: CHF5,828 Mil
  • GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score

Get the complete analysis for XSWX:BMY

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.31
Price
CHF45.07
GF Value